Search Results By Date:
Showing 46 - 60 of 64 results
  • Mazza JJ, Glurich IE, Liang H, Yale SH, Peters TL, Medlin SC. (2005 September). Risk assessment model for venothromboembolism in post-hospitalized patients. Int Angiol. 24(3):250-254.
    PubMed ID: 16158034
  • Nelson J, Berg RL, Glurich IE, Bryce DA. (2005 September). Intradiscal electrothermal annuloplasty therapy: a case series study leading to new considerations. WMJ. 104(6):39-46.
    PubMed ID: 16218315
  • Caldwell MD, Schmelzer JR, Berg RL, Glurich IE, Vidaillet HJ, Burmester JK,...Wilke RA [including Yale SH, Hillman MA.] (2005 August). A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 3(3):137-145.
    PubMed ID: 16160068
  • Goldberg JW, Habash-Bseiso D, Glurich IE, Yale SH. (2005 July). Serologic testing in connective tissue diseases. Clin Med Res. 3(3):190-193.
    PubMed ID: 16160075
  • Glurich IE, Yale SH. (2005 June). Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med. 11(3):433-439.
    PubMed ID: 15992226
  • Caldwell MD, Berg RL, Glurich IE, Burmester JK, Hillman MA, Wilke RA. (2004 August). Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics. 14(8):539-547.
    PubMed ID: 15284536
  • McCauley CS, Shukla SK, Haselby RC, Tak T, Reed KD. (2002 July). An update on the epidemiology, pathogenesis and management of infective endocarditis with emphasis on <em>Staphylococcus aureus</em>. WMJ. 101(7):24-33.
    PubMed ID: 12426917
  • Glurich IE, Grossi S, Albini B, Ho A, Shah R, Zeid R,...De Nardin E. (2002 March). Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol. 9(2):425-32.
    PubMed ID: 11874889
  • Haselby RC, Qutaishat S, Vandermause MF. (2002). Prevalence of Vancomycin resistant enterococcus (VRE) in hospitalized patients as compared to non-hospitalized patients. The Society for Healthcare Epidemiology of America (SHEA) Annual Meeting.
  • McCauley CS, Shukla SK, Haselby RC, Tak T, Reed KD. (2002). Second case of infective endocarditis caused by Gemella sanguinis. WMJ. 101(3):37-39.
    PubMed ID: 12109199
  • Glurich IE, Genco RJ, De Nardin E, Haraszthy V, Zambon J. (2001 February). Overview of risk factors for periodontal disease and implications for diabetes and cardiovascular disease. Compend Contin Educ Dent. 22(2 Spec No):21-3.
    PubMed ID: 19248254
  • Onitilo AA, Glurich IE. (2000). Test Chapter In: Doe J, Example A (Ed.), ABC (Vol. 3). (pp. 102-210). Springer.
  • Haselby RC, Malawista SE, Bryant G, Sigal LH, Zahradnik JM, Lavin P,...Molloy PJ. (1998 July). A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med. 339(4):216-222.
    PubMed ID: 9673299
  • Haselby RC, Adams EM, Gudmundsson S, Yocum DE, Craig WA, Sundstrom WR. (1985 June). Streptococcal myositis. Arch Intern Med. 145(6):1020-1023.
    PubMed ID: 3890787
  • Haselby RC, Kettrick MAlice, Motszko CS, Mitchell PD, Baldauf MC, Marx JJ. (1985 January). A randomized trial of transfer factor therapy in the treatment of herpes zoster infections. Immunology & Allergy Practice. 7(1):37-42.